Avid Bioservices Inc (CDMO)

[biopharm]

Hakan Mellstedt : Peregrine Pharmaceuticals KOL

another possible collaboration re: ROR1 and ROR2

Kancera strengthens patent rights related to ROR antibody therapy

..
..
..
About ROR
ROR is a family of receptor tyrosine kinase receptors originally reported to be linked to fetus development and consists of two receptors, ROR1 and ROR2. Today it is also known that ROR receptors play a role also for cancer cells. It has been shown that inhibition of ROR causes certain cancer cells to eliminate themselves through apoptosis. Since ROR receptors are not present in healthy cells in adults, it is anticipated that a drug targeting ROR will selectively attack the tumor much more forcefully than healthy tissue.

Kancera’s co-founder Professor Håkan Mellstedt has shown that Kancera´s ROR inhibitors are capable of killing cancer cells originating from pancreas and as well as leukemic cells. Professor Mellstedt and other scientists have further shown that ROR is a potential therapeutic target also in prostate-, breast- and lung cancer.

..
..
http://www.kancera.com/en/Press/Press-releases/Press-release/?releaseid=680359

Patent Issued Jan 2014:

https://patents.justia.com/inventor/hakan-mellstedt